AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03414281 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TPVB
Description: The patient is placed in the lateral position, the spinous processes of T10 are identified and marks are made 2cm lateral to the spinous processes. The linear(L12-3) probe of Philips CX50 is placed transversally at the mark to identify the paravertebral space. Then a 22-G needle is inserted in-plane from lateral to medial and advanced until the tip reached the paravertebral space surrounded by the parietal pleura and the superior costotransverse ligament. 0.4 ml/kg 0.5% ropivacaine with 1: 200,000 adrenaline is injected into the paravertebral space of T10.~Followed by IPCA in the first 48h after surgery: morphine boluses: 1.5-2 mg, lockout time :10 min, 1h limitation: 6-8 mg morphine.
Study NCT04137029 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formoterol
Description: The participants will receive inhalation of formoterol 12 micrograms
Study NCT04137029 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium Bromide
Description: The participants will receive inhalation of tiotropium bromide 18 mkg once
Study NCT04137029 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: metacholine test
Description: The participants will receive inhalation of metacholine once
Study NCT00631696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: pregabalin 600 mg given twice a day
Study NCT00631696 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT00002854 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Study NCT00002854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Study NCT00002854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Study NCT00002854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Study NCT00002854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Study NCT00002854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ifosfamide
Study NCT00002854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mesna
Study NCT00002854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Study NCT00002854 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Study NCT04088643 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial alternating current stimulation
Description: The alternating current is administered through medical grade conductive pads that are produced specifically for the Nexalin technology. The pads are places on the forehead and behind each ear, and are connected to the Nexalin device with thin cables. Intervention will be implemented with a tACS device with 4Hz frequency and a peak-to-peak amplitude of 15mA, 30 one-hour sessions in 3 weeks (21 days).
Study NCT04088643 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham stimulation
Description: Electrodes will also be put on patient's forehead and behind each ear. The sham stimulator has the exactly same appearance with the true stimulator. Participants and operators cannot determine whether the stimulator is true based on its appearance or patients' feelings. However, when the device is started, no current flows through the electrodes. Participants in this controlled group will also receive sham stimulations with 30 one-hour sessions in 21 days.
Study NCT02777619 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.0ng/ml Dexmedetomidine
Description: Dexmedetomidine target plasma concentration is 0.0ng/ml
Study NCT02777619 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.4ng/ml Dexmedetomidine
Description: Dexmedetomidine target plasma concentration is 0.4ng/ml
Study NCT02777619 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.6ng/ml Dexmedetomidine
Description: Dexmedetomidine target plasma concentration is 0.6ng/ml
Study NCT02777619 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.8ng/ml Dexmedetomidine
Description: Dexmedetomidine target plasma concentration is 0.8ng/ml
Study NCT02777619 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Propofol
Study NCT02777619 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Study NCT04452032 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dental avulsion
Description: Before radiotherapy, each subject undergoes a dental evaluation and if it is necessary, dental avulsions if their long-term survival is compromised (see in section 6.1.2) and if they are located in an area at risk to receive more than 40 Gy, so to develop osteoradionecrosis of the jaw. The avulsions should be performed as far as possible from the start of radiotherapy (RT) namely at least 2 weeks before irradiation to allow mucosal healing.
Study NCT04452032 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiotherapy:~All Subjects will be treated by simultaneous integrated boost (SIB) intensity modulated radiotherapy (IMRT) / volumetric modulated arc therapy (VMAT).
Study NCT02704260 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: GENETIC ANALYSIS
Description: prélevement blood to search for a genetic cause of vascular endofibrose. Search genetic mutations in 5 subjects.
Study NCT01160211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lapatinib
Description: 1000 mg by mouth once a day
Study NCT01160211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: Loading dose of 8 mg/kg IV followed by the maintenance dose of 6 mg/kg IV every 3 weeks
Study NCT01160211 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: trastuzumab
Description: Loading dose of 8 mg/kg IV followed by the maintenance dose of 6 mg/kg IV every 3 weeks
Study NCT01160211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aromatase inhibitor
Description: Aromatase inhibitor (either letrozole, anastrozole, or exemestane) of investigator's choice given by mouth once daily
Study NCT01160211 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aromatase inhibitor
Description: Aromatase inhibitor (either letrozole, anastrozole, or exemestane) of investigator's choice given by mouth once daily
Study NCT01160211 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lapatinib
Description: 1500 mg by mouth once daily
Study NCT00676338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exenatide once weekly
Description: subcutaneous injection, 2mg, once weekly plus placebo oral once daily
Study NCT00676338 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin
Description: oral, 1000-2500mg, daily plus placebo once weekly subcutaneous injection
Study NCT00676338 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sitagliptin
Description: oral, 100 mg, daily plus placebo once weekly subcutaneous injection
Study NCT00676338 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pioglitazone
Description: oral, 30-45mg, daily plus placebo once weekly subcutaneous injection
Study NCT01699490 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoxetine + Valsartan
Description: The curative effect of fluoxetine add-on valsartan 40 mg per day for 12 weeks therapy in the treatment of major depressive disorder.
Study NCT01699490 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluoxetine + Placebo
Description: The curative effect of fluoxetine add-on placebo therapy in the treatment of major depressive disorder.
Study NCT04238416 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Branched chain amino acid
Description: Intravenous branched chain amino acids will be given for 3 days to patients in experimental arm
Study NCT04238416 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactulose
Description: Oral lactulose will be given to patients in both arms
Study NCT04238416 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lactulose
Description: Oral lactulose will be given to patients in both arms
Study NCT04226560 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 41% Silicone Hydrogel Soft Contact Lenses(SHSCL)
Description: Silicone Hydrogel
Study NCT04226560 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ACUVUE® VITA™ (senofilcon C) Brand (Soft) Contact Lens
Description: Senofilcon C (USFDA Device License #K160212)
Study NCT04226560 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Contact Lens Care Product
Description: Cefatrizine (propylene Glycol), Sodium Citrate (sodium Citrate Tribasic), Sodium Chloride, Sodium Borate (sodium Biboratesodium Tetraborate, Polyquaternium -1, Hydrochloric Acid, Sodium Hydroxide, Water Purified ( Eq to Aqueous Purified Or Purified Water ), Tetronic 1304, Myristamidopropyl Dimethylamine, Nonanoyl Ethylenediaminetriacetic Acid
Study NCT04226560 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Contact Lens Care Product
Description: Cefatrizine (propylene Glycol), Sodium Citrate (sodium Citrate Tribasic), Sodium Chloride, Sodium Borate (sodium Biboratesodium Tetraborate, Polyquaternium -1, Hydrochloric Acid, Sodium Hydroxide, Water Purified ( Eq to Aqueous Purified Or Purified Water ), Tetronic 1304, Myristamidopropyl Dimethylamine, Nonanoyl Ethylenediaminetriacetic Acid
Study NCT04226560 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Contact Lens Case
Description: Alcon Soft (hydrophilic) Contact Lens Case (Non-Sterile)
Study NCT04226560 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Contact Lens Case
Description: Alcon Soft (hydrophilic) Contact Lens Case (Non-Sterile)
Study NCT01826773 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CardioPET™
Description: CardioPET™ will be intravenously injected to each subject as a single radio-labeled dose of up to 8 mCi (296 MBq).
Study NCT03719443 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VIS649
Description: Single IV dose of study product on Day 1 of study
Study NCT03719443 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Singe IV dose of placebo administered via IV on Day 1 of study
Study NCT04053179 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Patch validation
Description: Use of connected patch to collect blood pressure, heart rate, respiratory rate, arterial oxygen saturation and temperature
Study NCT03312777 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omnitram
Description: Omnitram tablets overencapsulated
Study NCT03312777 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol
Description: Tramadol tablet overencapsulated
Study NCT03312777 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Microcrystalline powder overencapsulated
Study NCT04165798 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Tumor Imaging
Description: Participants will undergo tumor imaging using either a magnetic resonance imaging (MRI) scan or a computed tomography (CT) scan.
Study NCT04165798 — intervention group
Intervention type: PROCEDURE
Intervention: Tumor Tissue Collection
Description: Participants without archival tumor tissue samples will undergo tumor tissue collection for newly obtained tumor tissue.
Study NCT04165798 — intervention group
Intervention type: PROCEDURE
Intervention: Blood Sample Collection
Description: Participants will have blood samples drawn for analysis of:~* genetics~* ribonucleic acid (RNA)~* serum biomarker~* plasma biomarker~* circulating tumor DNA (ctDNA)
Study NCT00657280 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: No one is blinded to the treatments.
Study NCT03363256 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TES-NAV
Description: Internet-delivered psychosocial treatment grounded in the community reinforcement approach plus contingency management adapted for AI/AN
Study NCT03549455 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure Therapy and Self Distancing
Description: Weeks 1 and 2 will be introductory sessions (background, rationale, motivational enhancement); Weeks 3 \& 4 will have Exposure therapy with Self-Distancing; Weeks 5 \& 6 will have Exposure therapy only; Weeks 7 \& 8 will have Exposure therapy with Self-Distancing;
Study NCT03363256 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TAU
Description: Standard outpatient addiction treatment
Study NCT03363256 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TAU
Description: Standard outpatient addiction treatment
Study NCT03244176 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Avelumab
Description: All participants will receive the following treatment:~Induction phase Avelumab at a dose of 10 mg/kg as a 1hour intravenous (IV) infusion once every 2 weeks for 2 cycles Plus Rituximab at a dose of 375mg/m2 as an IV infusion over at least 1 hour once every 2 weeks for 2 treatments~Then:~RCHOP - All participants will receive RCHOP chemotherapy treatment for 6 cycles. Each cycle will last for 21 days. Rituximab, cyclophosphamide, doxorubicin, and vincristine are given on the first day of each cycle by intravenous infusion. Prednisone is given orally from Day 1 until Day 5 of each cycle.~Then:~Maintenance phase - All participants will receive Avelumab at a dose of 10 mg/kg as a 1hour intravenous (IV) infusion once every 2 weeks for 6 cycles.
Study NCT03059082 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Recovery Navigator on an as needed basis up to 6 months
Description: This group will undergo contact with Recovery Navigator on an as needed basis up to 6 months and then have a 3 month and 6 month follow-up visit.
Study NCT03059082 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Recovery Navigator prior to hospital discharge
Description: This group will undergo one interaction with Recovery Navigator prior to hospital discharge and then have a 3 month and 6 month follow-up visit.
Study NCT03059082 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No interaction with Recovery Navigator
Description: This group will not have any interaction with Recovery Navigator. They will have a 3 month and 6 month follow-up visit.
Study NCT04708743 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Automatic Tongue Diagnosis System
Description: tongue image capture tongue images by Automatic Tongue Diagnosis System
Study NCT00941031 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AIN457
Study NCT00941031 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AIN457A
Description: Induction with monthly injections - Monthly: secukinumab (AIN457) 150 mg s.c. administered at weeks 1, 5, 9
Study NCT00941031 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AIN457A
Description: Early loading induction - Early: secukinumab (AIN457) 150 mg s.c. administered at weeks 1, 2, 3, 5
Study NCT00941031 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo - Placebo: Placebo administered at weeks 1, 2, 3, 5, 9
Study NCT03015831 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colchicine
Description: Colchicine will be given to open heart surgery patients
Study NCT03015831 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo Oral Tablet will be given to open heart surgery patients according to randomization
Study NCT01611909 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: p-menthane-3,8-diol oil
Description: Apply topically to affected area twice daily
Study NCT01611909 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: p-menthane-3,8-diol oil
Description: Apply topically to affected area twice daily
Study NCT00803426 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sciatic nerve blockade for ankle/foot surgery
Description: Injection of local anesthetic near the nerve to achieve anesthesia.
Study NCT00803426 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sciatic nerve blockade for ankle/foot surgery
Description: Injection of local anesthetic near the nerve to achieve anesthesia.
Study NCT02261870 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI T2 quantification
Description: MRI acquisitions will be performed according to the already described method based on conventional Fast Spin Echo sequences and with an additional calibration pad positioned on the patient thorax (dedicated pad made by the Nancy CIC-IT with stable and adapted T2). MRI will be performed if possible before the biopsy and otherwise the radiologist will be kept blinded of the biopsy results.
Study NCT00983476 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: in-person MOVE! SMI
Description: Individual and group in-person sessions that deliver manualized MOVE! curriculum adapted for use with individuals with cognitive deficits (often found in individuals with severe mental illness (SMI))
Study NCT00983476 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: web-based MOVE! SMI
Description: online sessions that deliver manualized MOVE! curriculum adapted for use with individuals with cognitive deficits (often found in individuals with severe mental illness (SMI))
Study NCT01363466 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hysterectomy
Study NCT02722616 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound scan of the pancreas
Description: A 4D ultrasound scan will be acquired at the time at simulation and used as a reference ultrasound image for localizing tracking target. The ultrasound probe will be placed at the abdominal area to monitor the pancreas motion. The probe will remain in place during the CT scan. Patient setup and the ultrasound probe location will be recorded so that the same setup can be reproduced during treatment delivery.
Study NCT02722616 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound scan of the Liver
Description: A 4D ultrasound scan will be acquired at the time at simulation and used as a reference ultrasound image for localizing tracking target. The ultrasound probe will be placed at the abdominal area to monitor the liver motion. The probe will remain in place during the CT scan. Patient setup and the ultrasound probe location will be recorded so that the same setup could be reproduced during treatment delivery. The ultrasound probe in the CT image will be contoured and radiation beams that directly pass through the ultrasound probe will be avoided.
Study NCT02722616 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Reference ultrasound
Description: A reference ultrasound scan will be conducted on each subject during breath-hold. Subjects will be required to lie in supine position and engaged with ABC; an ultrasound probe will be placed at the abdomen area with minimal pressure applied. Continuous motion monitoring is achieved by acquiring 4D ultrasound images using a motorized 3D ultrasound probe to image the pancreas, liver and other intra-abdominal organs continuously. Several 4D ultrasound scans will be collected during subsequent breath-holds that serve as secondary images.
Study NCT00535028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AER 001
Description: AER 001 25 mgs s.c. once daily for 28 days
Study NCT00535028 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: sterile saline
Study NCT01477099 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Toothbrushing with a manual brush
Description: Toothbrushing with a manual brush
Study NCT05317962 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Transthoracic echocardiogram
Description: Abbreviated transthoracic echocardiogram
Study NCT04407832 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: heat probe or hemoclip
Description: for hemostasis
Study NCT02230111 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Energy restriction plus CDR
Description: Subjects will receive a reduced-calorie low energy density diet which will provide 85% of their energy needs for a period of 4 weeks. In the condition in which an increase in CDR will be induced, women will be told at the beginning of the study and will be reminded throughout the 4-week duration of the experimental condition that they are on a low-calorie diet and that it is important not to eat more than what is provided and that they should strictly avoid non-study food if they want to lose weight and improve their blood pressure. Subjects will receive feedback about their weight trajectory. After the 4-week controlled intervention women will then receive further information and advices to pursue their weight loss on their own and keeping on with strategies relying on an increase in CDR.
Study NCT02230111 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Energy restriction without CDR
Description: Subjects will receive the same low-calorie diet (85% of their energy needs) for 4 weeks but will not be told that they are on an energy-deficit diet. They will be told at the beginning of the study that the food provided cover all their nutrient needs and that they should eat until satiation. There will be no emphasis on body weight and subjects will be reminded that the aim of the intervention is to document the effects of a diet rich in vegetables and fruits on blood pressure. After the 4-week controlled diet, participants will be taught about the impact of a low energy density diet on satiation and satiety. They will receive further information and advices (with non-restrictive messages) to incorporate more vegetables and fruits in their usual diet.
Study NCT04164524 — intervention group
Intervention type: DRUG
Intervention: Gentamycin
Description: Gentamycin 160 mg spray applied over the mesh